Sequential FDG-PET/CT after Neoadjuvant Chemotherapy is a Predictor of Histopathologic Response in Patients with Head and Neck Squamous Cell Carcinoma

被引:27
作者
Kikuchi, Masahiro [1 ]
Shinohara, Shogo [1 ]
Nakamoto, Yuji [2 ]
Usami, Yu [3 ]
Fujiwara, Keizo [1 ]
Adachi, Tsunemichi [4 ]
Hori, Shin-ya [5 ]
Tona, Yosuke [1 ]
Yamazaki, Hiroshi [1 ]
Imai, Yukihiro [3 ]
Naito, Yasushi [1 ]
机构
[1] Gen Hosp, Dept Otolaryngol, Kobe City Med Ctr, Chuo Ku, Kobe, Hyogo 6500046, Japan
[2] Kyoto Univ Hosp, Dept Diagnost Radiol, Kyoto 606, Japan
[3] Gen Hosp, Kobe City Med Ctr, Dept Clin Pathol, Kyoto, Japan
[4] Kyoto Univ Hosp, Dept Otolaryngol, Kyoto 606, Japan
[5] Shizuoka Prefectural Gen Hosp, Dept Otolaryngol, Shizuoka, Japan
关键词
FDG-PET/CT; Head and neck squamous cell carcinoma; Histopathologic response; Neoadjuvant chemotherapy; PREVIOUSLY UNTREATED PATIENTS; SOLID TUMORS; PREOPERATIVE CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; GASTRIC-CARCINOMA; CANCER; RADIOTHERAPY; SURVIVAL; THERAPY; TRIAL;
D O I
10.1007/s11307-010-0364-3
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
To evaluate whether 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) more accurately predicts the histopathologic response to neoadjuvant chemotherapy (NAC) than magnetic resonance imaging (MRI) in patients with head and neck squamous cell carcinoma (HNSCC). Sixteen patients with HNSCC underwent FDG-PET/CT and MRI scans before and after one cycle of NAC, followed by surgical resection. The 26 surgically resected specimens of the 16 patients were analyzed. Decreases in maximum standardized uptake value (SUVmax) or in tumor maximum size (diameter(max)) were calculated, and their accuracies for the prediction of histopathologic response were evaluated. In histopathologic responders (n = 7), percent decreases in SUVmax were significantly higher (P < 0.001) than in non-responders (n = 19). Applying a cut-off point of 55.5%, the histopathologic response could be predicted with a sensitivity and specificity of 86% and 95%, respectively. FDG-PET/CT can predict histopathologic NAC responses with higher accuracy than MRI in HNSCC patients.
引用
收藏
页码:368 / 377
页数:10
相关论文
共 33 条
[1]  
ALKOURAINY K, 1987, CANCER-AM CANCER SOC, V59, P233, DOI 10.1002/1097-0142(19870115)59:2<233::AID-CNCR2820590210>3.0.CO
[2]  
2-X
[3]   Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers [J].
Andrade, Regiane S. ;
Heron, Dwight E. ;
Degirmenci, Berna ;
Filho, Pedro A. A. ;
Branstetter, Barton F. ;
Seethala, Raja R. ;
Ferris, Robert L. ;
Avril, Norbert .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (05) :1315-1322
[4]   Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy [J].
Becker, K ;
Mueller, JD ;
Schulmacher, C ;
Ott, K ;
Fink, U ;
Busch, R ;
Böttcher, K ;
Siewert, JR ;
Höfler, H .
CANCER, 2003, 98 (07) :1521-1530
[5]   FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas [J].
Benz, Matthias R. ;
Czernin, Johannes ;
Allen-Auerbach, Martin S. ;
Tap, William D. ;
Dry, Sarah M. ;
Elashoff, David ;
Chow, Kira ;
Evilevitch, Vladimir ;
Eckardt, Jeff J. ;
Phelps, Michael E. ;
Weber, Wolfgang A. ;
Eilber, Fritz C. .
CLINICAL CANCER RESEARCH, 2009, 15 (08) :2856-2863
[6]   Early Changes in 2-Deoxy-2-[18F]Fluoro-D-Glucose Metabolism in Squamous-Cell Carcinoma During Chemotherapy in Vivo and In Vitro [J].
Bjurberg, Maria ;
Henriksson, Eva ;
Brun, Eva ;
Ekblad, Lars ;
Ohlsson, Tomas ;
Brun, Arne ;
Kjellen, Elisabeth .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (03) :327-332
[7]   FDG pet studies during treatment:: Prediction of therapy outcome in head and neck squamous cell carcinoma [J].
Brun, E ;
Kjellén, E ;
Tennvall, J ;
Ohlsson, T ;
Sandell, A ;
Perfekt, R ;
Wennerberg, J ;
Strand, SE .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (02) :127-135
[8]  
CLARK JR, 1988, SEMIN ONCOL, V15, P35
[9]  
COGNETTI F, 1988, CANCER-AM CANCER SOC, V62, P251, DOI 10.1002/1097-0142(19880715)62:2<251::AID-CNCR2820620205>3.0.CO
[10]  
2-J